Pharmaceutical Executive Daily: argenx Acquires Unnatural Products Inc.

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, argenx acquires Unnatural Products for up to $1.15 billion to add macrocyclic peptide discovery to its antibody engineering, GiftHealth’s Chip Parkinson argues single-partner platforms can transform a broken prescription journey, and Partha Anbil contends the industry must compete on auditable net value as Medicare negotiation, PBM reform, and cash-pay channels converge.

argenx signs a definitive agreement to acquire the remaining shares of Unnatural Products, in which it already held a minority stake, in a deal worth up to approximately $1.15 billion combining a $550 million upfront cash payment and up to $595 million in milestones. The acquisition adds a macrocyclic peptide discovery platform intended to complement argenx’s antibody engineering and open paths toward oral and long-acting medicines, with Unnatural Products continuing to operate from its Santa Cruz site.

GiftHealth CEO Chip Parkinson argues that the traditional prescription journey, riddled with delays, high costs, and fragmented data, needs transformation rather than incremental fixes. He makes the case that single-partner platforms unifying manufacturers, prescribers, and patients can close those gaps, cut costs, and improve treatment adherence.

Finally, life sciences adviser Partha Anbil contends that as Medicare negotiation, PBM reform, and cash-pay channels converge, the industry’s durable response isn’t simply lower list prices but competition on auditable net value. He points to the first 10 Medicare maximum fair prices taking effect in January 2026, with discounts of 38% to 79% against 2023 list prices, as evidence that manufacturers must now build net-economics maps by product and channel rather than rely on single discount figures.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.